InfuSystem Holdings, Inc. (INFU) Stock Competitors & Peer Comparison
See (INFU) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INFU | $10.16 | +1.40% | 205M | 26.74 | $0.38 | N/A |
| BDX | $158.08 | +3.39% | 57.3B | 11.75 | $13.45 | +2.37% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.37% |
| MDLN | $43.19 | +3.50% | 36.5B | 50.22 | $0.86 | N/A |
| WST | $365.74 | +0.20% | 25.8B | 45.89 | $7.97 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $74.20 | +3.13% | 14.5B | 16.27 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.37% |
| BAX | $22.65 | +4.43% | 11.7B | 10.89 | $2.08 | +0.88% |
| ATR | $126.98 | +1.38% | 8.1B | 22.20 | $5.72 | +1.49% |
Stock Comparison
INFU vs BDX Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, BDX has a market cap of 57.3B. Regarding current trading prices, INFU is priced at $10.16, while BDX trades at $158.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas BDX's P/E ratio is 11.75. In terms of profitability, INFU's ROE is +0.14%, compared to BDX's ROE of +0.05%. Regarding short-term risk, INFU is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check BDX's competition here
INFU vs BDXA Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, INFU is priced at $10.16, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas BDXA's P/E ratio is 45.70. In terms of profitability, INFU's ROE is +0.14%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, INFU is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check BDXA's competition here
INFU vs MDLN Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, MDLN has a market cap of 36.5B. Regarding current trading prices, INFU is priced at $10.16, while MDLN trades at $43.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas MDLN's P/E ratio is 50.22. In terms of profitability, INFU's ROE is +0.14%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, INFU is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check MDLN's competition here
INFU vs WST Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, WST has a market cap of 25.8B. Regarding current trading prices, INFU is priced at $10.16, while WST trades at $365.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas WST's P/E ratio is 45.89. In terms of profitability, INFU's ROE is +0.14%, compared to WST's ROE of +0.18%. Regarding short-term risk, INFU is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check WST's competition here
INFU vs HOLX Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, INFU is priced at $10.16, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas HOLX's P/E ratio is 31.54. In terms of profitability, INFU's ROE is +0.14%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check HOLX's competition here
INFU vs COO Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, COO has a market cap of 14.5B. Regarding current trading prices, INFU is priced at $10.16, while COO trades at $74.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas COO's P/E ratio is 16.27. In terms of profitability, INFU's ROE is +0.14%, compared to COO's ROE of +0.03%. Regarding short-term risk, INFU is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check COO's competition here
INFU vs BDXB Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, INFU is priced at $10.16, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas BDXB's P/E ratio is 7.60. In terms of profitability, INFU's ROE is +0.14%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, INFU is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check BDXB's competition here
INFU vs BAX Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, BAX has a market cap of 11.7B. Regarding current trading prices, INFU is priced at $10.16, while BAX trades at $22.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas BAX's P/E ratio is 10.89. In terms of profitability, INFU's ROE is +0.14%, compared to BAX's ROE of -0.16%. Regarding short-term risk, INFU is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check BAX's competition here
INFU vs ATR Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ATR has a market cap of 8.1B. Regarding current trading prices, INFU is priced at $10.16, while ATR trades at $126.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ATR's P/E ratio is 22.20. In terms of profitability, INFU's ROE is +0.14%, compared to ATR's ROE of +0.14%. Regarding short-term risk, INFU is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check ATR's competition here
INFU vs RGEN Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, RGEN has a market cap of 8B. Regarding current trading prices, INFU is priced at $10.16, while RGEN trades at $142.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas RGEN's P/E ratio is 79.11. In terms of profitability, INFU's ROE is +0.14%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, INFU is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check RGEN's competition here
INFU vs AVTR Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, AVTR has a market cap of 7B. Regarding current trading prices, INFU is priced at $10.16, while AVTR trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas AVTR's P/E ratio is 12.14. In terms of profitability, INFU's ROE is +0.14%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, INFU is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check AVTR's competition here
INFU vs BLCO Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, INFU is priced at $10.16, while BLCO trades at $17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas BLCO's P/E ratio is 26.40. In terms of profitability, INFU's ROE is +0.14%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, INFU is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check BLCO's competition here
INFU vs TFX Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, TFX has a market cap of 5.9B. Regarding current trading prices, INFU is priced at $10.16, while TFX trades at $133.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas TFX's P/E ratio is 12.50. In terms of profitability, INFU's ROE is +0.14%, compared to TFX's ROE of -0.28%. Regarding short-term risk, INFU is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check TFX's competition here
INFU vs STVN Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, STVN has a market cap of 5.2B. Regarding current trading prices, INFU is priced at $10.16, while STVN trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas STVN's P/E ratio is 30.65. In terms of profitability, INFU's ROE is +0.14%, compared to STVN's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check STVN's competition here
INFU vs MMSI Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, MMSI has a market cap of 4.2B. Regarding current trading prices, INFU is priced at $10.16, while MMSI trades at $71.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas MMSI's P/E ratio is 18.18. In terms of profitability, INFU's ROE is +0.14%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, INFU is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check MMSI's competition here
INFU vs ICUI Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, INFU is priced at $10.16, while ICUI trades at $154.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ICUI's P/E ratio is 19.35. In terms of profitability, INFU's ROE is +0.14%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, INFU is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check ICUI's competition here
INFU vs WRBY Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, WRBY has a market cap of 3.6B. Regarding current trading prices, INFU is priced at $10.16, while WRBY trades at $29.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas WRBY's P/E ratio is 108.37. In terms of profitability, INFU's ROE is +0.14%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, INFU is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check WRBY's competition here
INFU vs HAE Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, HAE has a market cap of 3.4B. Regarding current trading prices, INFU is priced at $10.16, while HAE trades at $75.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas HAE's P/E ratio is 15.10. In terms of profitability, INFU's ROE is +0.14%, compared to HAE's ROE of +0.11%. Regarding short-term risk, INFU is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check HAE's competition here
INFU vs LMAT Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, LMAT has a market cap of 2.4B. Regarding current trading prices, INFU is priced at $10.16, while LMAT trades at $102.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas LMAT's P/E ratio is 39.88. In terms of profitability, INFU's ROE is +0.14%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, INFU is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check LMAT's competition here
INFU vs XRAY Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, XRAY has a market cap of 2.3B. Regarding current trading prices, INFU is priced at $10.16, while XRAY trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas XRAY's P/E ratio is 8.15. In terms of profitability, INFU's ROE is +0.14%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, INFU is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check XRAY's competition here
INFU vs PLSE Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, PLSE has a market cap of 2B. Regarding current trading prices, INFU is priced at $10.16, while PLSE trades at $29.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas PLSE's P/E ratio is -26.55. In terms of profitability, INFU's ROE is +0.14%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, INFU is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check PLSE's competition here
INFU vs ATRC Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, INFU is priced at $10.16, while ATRC trades at $31.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ATRC's P/E ratio is 987.27. In terms of profitability, INFU's ROE is +0.14%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, INFU is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check ATRC's competition here
INFU vs KMTS Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, INFU is priced at $10.16, while KMTS trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas KMTS's P/E ratio is -9.84. In terms of profitability, INFU's ROE is +0.14%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, INFU is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check KMTS's competition here
INFU vs STAA Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, STAA has a market cap of 1.4B. Regarding current trading prices, INFU is priced at $10.16, while STAA trades at $27.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas STAA's P/E ratio is 48.75. In terms of profitability, INFU's ROE is +0.14%, compared to STAA's ROE of -0.06%. Regarding short-term risk, INFU is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check STAA's competition here
INFU vs BLFS Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, BLFS has a market cap of 1.4B. Regarding current trading prices, INFU is priced at $10.16, while BLFS trades at $28.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas BLFS's P/E ratio is -133.00. In terms of profitability, INFU's ROE is +0.14%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, INFU is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check BLFS's competition here
INFU vs QDEL Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, QDEL has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $10.16, while QDEL trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas QDEL's P/E ratio is 13.62. In terms of profitability, INFU's ROE is +0.14%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, INFU is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check QDEL's competition here
INFU vs AZTA Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, AZTA has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $10.16, while AZTA trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas AZTA's P/E ratio is 57.42. In terms of profitability, INFU's ROE is +0.14%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, INFU is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check AZTA's competition here
INFU vs ATRI Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, INFU is priced at $10.16, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ATRI's P/E ratio is 64.50. In terms of profitability, INFU's ROE is +0.14%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, INFU is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check ATRI's competition here
INFU vs NNNN Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, NNNN has a market cap of 557.4M. Regarding current trading prices, INFU is priced at $10.16, while NNNN trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas NNNN's P/E ratio is 183.53. In terms of profitability, INFU's ROE is +0.14%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, INFU is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check NNNN's competition here
INFU vs ANGO Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ANGO has a market cap of 540.9M. Regarding current trading prices, INFU is priced at $10.16, while ANGO trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ANGO's P/E ratio is -37.40. In terms of profitability, INFU's ROE is +0.14%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, INFU is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check ANGO's competition here
INFU vs OSUR Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, OSUR has a market cap of 299.5M. Regarding current trading prices, INFU is priced at $10.16, while OSUR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas OSUR's P/E ratio is -5.24. In terms of profitability, INFU's ROE is +0.14%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, INFU is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check OSUR's competition here
INFU vs UTMD Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, UTMD has a market cap of 231.7M. Regarding current trading prices, INFU is priced at $10.16, while UTMD trades at $72.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas UTMD's P/E ratio is 21.53. In terms of profitability, INFU's ROE is +0.14%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, INFU is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check UTMD's competition here
INFU vs SMTI Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, SMTI has a market cap of 227.6M. Regarding current trading prices, INFU is priced at $10.16, while SMTI trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas SMTI's P/E ratio is -414.00. In terms of profitability, INFU's ROE is +0.14%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, INFU is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check SMTI's competition here
INFU vs KRMD Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, KRMD has a market cap of 206.2M. Regarding current trading prices, INFU is priced at $10.16, while KRMD trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas KRMD's P/E ratio is -112.25. In terms of profitability, INFU's ROE is +0.14%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, INFU is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check KRMD's competition here
INFU vs PDEX Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, PDEX has a market cap of 195.8M. Regarding current trading prices, INFU is priced at $10.16, while PDEX trades at $61.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas PDEX's P/E ratio is 21.60. In terms of profitability, INFU's ROE is +0.14%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, INFU is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check PDEX's competition here
INFU vs MBOT Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, MBOT has a market cap of 87M. Regarding current trading prices, INFU is priced at $10.16, while MBOT trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas MBOT's P/E ratio is -7.35. In terms of profitability, INFU's ROE is +0.14%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, INFU is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check MBOT's competition here
INFU vs AKYA Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, INFU is priced at $10.16, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas AKYA's P/E ratio is -1.34. In terms of profitability, INFU's ROE is +0.14%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, INFU is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check AKYA's competition here
INFU vs DXR Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, DXR has a market cap of 52.3M. Regarding current trading prices, INFU is priced at $10.16, while DXR trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas DXR's P/E ratio is 27.15. In terms of profitability, INFU's ROE is +0.14%, compared to DXR's ROE of +0.22%. Regarding short-term risk, INFU is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check DXR's competition here
INFU vs STSS Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, STSS has a market cap of 51.2M. Regarding current trading prices, INFU is priced at $10.16, while STSS trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas STSS's P/E ratio is -0.02. In terms of profitability, INFU's ROE is +0.14%, compared to STSS's ROE of -1.66%. Regarding short-term risk, INFU is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check STSS's competition here
INFU vs OMIC Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, INFU is priced at $10.16, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas OMIC's P/E ratio is -0.58. In terms of profitability, INFU's ROE is +0.14%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, INFU is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check OMIC's competition here
INFU vs IGAP Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, INFU is priced at $10.16, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas IGAP's P/E ratio is -10.52. In terms of profitability, INFU's ROE is +0.14%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, INFU is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check IGAP's competition here
INFU vs POCI Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, POCI has a market cap of 39.1M. Regarding current trading prices, INFU is priced at $10.16, while POCI trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas POCI's P/E ratio is -7.03. In terms of profitability, INFU's ROE is +0.14%, compared to POCI's ROE of -0.37%. Regarding short-term risk, INFU is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check POCI's competition here
INFU vs NEPH Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, NEPH has a market cap of 36.9M. Regarding current trading prices, INFU is priced at $10.16, while NEPH trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas NEPH's P/E ratio is 48.57. In terms of profitability, INFU's ROE is +0.14%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, INFU is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check NEPH's competition here
INFU vs MLSS Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, MLSS has a market cap of 30.3M. Regarding current trading prices, INFU is priced at $10.16, while MLSS trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas MLSS's P/E ratio is -5.70. In terms of profitability, INFU's ROE is +0.14%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, INFU is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check MLSS's competition here
INFU vs SDC Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, INFU is priced at $10.16, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas SDC's P/E ratio is -0.03. In terms of profitability, INFU's ROE is +0.14%, compared to SDC's ROE of -1.96%. Regarding short-term risk, INFU is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check SDC's competition here
INFU vs HBIO Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, HBIO has a market cap of 27.7M. Regarding current trading prices, INFU is priced at $10.16, while HBIO trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas HBIO's P/E ratio is -17.08. In terms of profitability, INFU's ROE is +0.14%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, INFU is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check HBIO's competition here
INFU vs IVC Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, INFU is priced at $10.16, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas IVC's P/E ratio is -0.79. In terms of profitability, INFU's ROE is +0.14%, compared to IVC's ROE of -0.46%. Regarding short-term risk, INFU is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check IVC's competition here
INFU vs RVP Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, RVP has a market cap of 21.9M. Regarding current trading prices, INFU is priced at $10.16, while RVP trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas RVP's P/E ratio is -2.21. In terms of profitability, INFU's ROE is +0.14%, compared to RVP's ROE of -0.08%. Regarding short-term risk, INFU is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check RVP's competition here
INFU vs ARTC Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ARTC has a market cap of 16.1M. Regarding current trading prices, INFU is priced at $10.16, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ARTC's P/E ratio is N/A. In terms of profitability, INFU's ROE is +0.14%, compared to ARTC's ROE of N/A. Regarding short-term risk, INFU is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check ARTC's competition here
INFU vs RGNT Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, RGNT has a market cap of 15.9M. Regarding current trading prices, INFU is priced at $10.16, while RGNT trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas RGNT's P/E ratio is -0.17. In terms of profitability, INFU's ROE is +0.14%, compared to RGNT's ROE of N/A. Regarding short-term risk, INFU is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check RGNT's competition here
INFU vs ZJYL Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ZJYL has a market cap of 15.3M. Regarding current trading prices, INFU is priced at $10.16, while ZJYL trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ZJYL's P/E ratio is 12.25. In terms of profitability, INFU's ROE is +0.14%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, INFU is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check ZJYL's competition here
INFU vs FEMY Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, FEMY has a market cap of 12.6M. Regarding current trading prices, INFU is priced at $10.16, while FEMY trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas FEMY's P/E ratio is -11.52. In terms of profitability, INFU's ROE is +0.14%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, INFU is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check FEMY's competition here
INFU vs NXGL Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, NXGL has a market cap of 5.2M. Regarding current trading prices, INFU is priced at $10.16, while NXGL trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas NXGL's P/E ratio is -1.45. In terms of profitability, INFU's ROE is +0.14%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, INFU is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check NXGL's competition here
INFU vs NSTG Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, INFU is priced at $10.16, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas NSTG's P/E ratio is -0.03. In terms of profitability, INFU's ROE is +0.14%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, INFU is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check NSTG's competition here
INFU vs POAI Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, INFU is priced at $10.16, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas POAI's P/E ratio is -0.03. In terms of profitability, INFU's ROE is +0.14%, compared to POAI's ROE of -107.05%. Regarding short-term risk, INFU is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check POAI's competition here
INFU vs LUCY Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, LUCY has a market cap of 3M. Regarding current trading prices, INFU is priced at $10.16, while LUCY trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas LUCY's P/E ratio is -0.45. In terms of profitability, INFU's ROE is +0.14%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, INFU is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check LUCY's competition here
INFU vs MHUA Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, INFU is priced at $10.16, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas MHUA's P/E ratio is 0.25. In terms of profitability, INFU's ROE is +0.14%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, INFU is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check MHUA's competition here
INFU vs NXGLW Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, NXGLW has a market cap of 2.1M. Regarding current trading prices, INFU is priced at $10.16, while NXGLW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas NXGLW's P/E ratio is -0.07. In terms of profitability, INFU's ROE is +0.14%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, INFU is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check NXGLW's competition here
INFU vs GMVD Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, INFU is priced at $10.16, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas GMVD's P/E ratio is -0.01. In terms of profitability, INFU's ROE is +0.14%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, INFU is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check GMVD's competition here
INFU vs GMVDW Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, INFU is priced at $10.16, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas GMVDW's P/E ratio is N/A. In terms of profitability, INFU's ROE is +0.14%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, INFU is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check GMVDW's competition here
INFU vs AVGR Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, INFU is priced at $10.16, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas AVGR's P/E ratio is -0.05. In terms of profitability, INFU's ROE is +0.14%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, INFU is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check AVGR's competition here
INFU vs LUCYW Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, INFU is priced at $10.16, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, INFU's ROE is +0.14%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, INFU is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check LUCYW's competition here
INFU vs GCTK Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, GCTK has a market cap of 181.6K. Regarding current trading prices, INFU is priced at $10.16, while GCTK trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas GCTK's P/E ratio is -0.02. In terms of profitability, INFU's ROE is +0.14%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, INFU is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for INFU.Check GCTK's competition here
INFU vs IIN Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, IIN has a market cap of 0. Regarding current trading prices, INFU is priced at $10.16, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas IIN's P/E ratio is 226.45. In terms of profitability, INFU's ROE is +0.14%, compared to IIN's ROE of -0.00%. Regarding short-term risk, INFU is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check IIN's competition here
INFU vs IVTY Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, INFU is priced at $10.16, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas IVTY's P/E ratio is -3.80. In terms of profitability, INFU's ROE is +0.14%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, INFU is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check IVTY's competition here
INFU vs ALOG Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, INFU is priced at $10.16, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ALOG's P/E ratio is 40.93. In terms of profitability, INFU's ROE is +0.14%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, INFU is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check ALOG's competition here
INFU vs HRC Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, HRC has a market cap of 0. Regarding current trading prices, INFU is priced at $10.16, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas HRC's P/E ratio is 41.92. In terms of profitability, INFU's ROE is +0.14%, compared to HRC's ROE of +0.14%. Regarding short-term risk, INFU is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check HRC's competition here
INFU vs APR Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, APR has a market cap of 0. Regarding current trading prices, INFU is priced at $10.16, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas APR's P/E ratio is 22.59. In terms of profitability, INFU's ROE is +0.14%, compared to APR's ROE of +9.81%. Regarding short-term risk, INFU is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check APR's competition here
INFU vs ATRS Comparison July 2026
INFU plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 205M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, INFU is priced at $10.16, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 26.74, whereas ATRS's P/E ratio is 14.95. In terms of profitability, INFU's ROE is +0.14%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, INFU is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for INFU.Check ATRS's competition here